Natixis Bleichroeder Downgrades WuXi PharmaTech (WX) to Hold
More News related to WX
- WuXi PharmaTech (WX) Posts Q3 non-GAAP EPS of $0.24, Tops by 9c
- WuXi PharmaTech Announces Third-Quarter 2009 Results
- Trading Radar for 11/17: Home Depot (HD), Saks (SKS), Target (TGT), Autodesk (ADSK), La-Z-Boy (LZB) Report
- Credit Suisse Downgrades WuXi PharmaTech (WX) to Neutral
- WuXi AppTec Receives 2009 Schering-Plough Excellence Award
More News related to Downgrades
- Keefe, Bruyette & Woods Downgrades First State Bancorporation (FSNM) to Market Perform
- Keefe, Bruyette & Woods Downgrades R&G Financial (RGFC) to Market Perform
Natixis Bleichroeder downgrades WuXi PharmaTech Inc. (NYSE: WX) from Buy to Hold with a $13 price target.
Shares of WX are up 18.6% today following second quarter results after the close.
WuXi PharmaTech (Cayman) Inc., through its subsidiaries, operates as a pharmaceutical, biotechnology, and medical device research and development outsourcing company in the People's Republic of China and the United States.
Related Categories
DowngradesStocks Mentioned
+0.29Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
